NEU Vs Reata, page-9

I came across the following clinical trial (SPG302) this this evening and I am wondering whether it may be complementary or potential competition for Trofinetide and NNZ-2591.

https://www.globenewswire.com/news-release/2023/07/10/2701531/0/en/Spinogenix-Receives-Approval-from-the-Australia-Human-Research-Ethics-Committee-to-Initiate-a-Phase-1-Human-Clinical-Trial-of-SPG302-a-Novel-Regenerative-Drug-for-the-Treatment-of-.html

"SAN DIEGO, July 10, 2023 (GLOBE NEWSWIRE) -- Spinogenix, Inc., a clinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today announced that it is open to enrollment having received approval from Australia’s Human Research Ethics Committee (HREC) on June 26th to start human clinical trials with its novel drug SPG302 for the treatment of Amyotrophic Lateral Sclerosis (ALS).

SPG302 is an orally bioavailable, blood-brain barrier penetrating synthetic small molecule. It has a unique mode of action; it induces an increase in synapses, the key connections between neurons that allow people to think, plan, remember and control motor functions, faculties that are diminished in neurodegenerative diseases like ALS. The drug has demonstrated improved cognition and motor behaviors in multiple animal models of neurodegenerative disorders."

"Dr. Merit Cudkowicz, Director of the Sean M. Healey and AMG Center for ALS at Massachusetts General Hospital, commented, “We are happy to see that Spinogenix is progressing into human trials. To my knowledge, this is the first clinical trial in ALS focused on regenerating synapses with a small molecule. It has the potential to be used in combination with many other treatments approved and in development.”

==>> I am wondering whether a combo trial with NNZ-2591 is a possibility ... food for thought


Look at that mouse run!!!

GLTA